Inebilizumab for Treatment of IgG4-Related Disease

Original Article

J.H. Stone, A. Khosroshahi, W. Zhang, E.D. Torre, K. Okazaki, Y. Tanaka, J.M. Löhr, N. Schleinitz, L. Dong, H. Umehara, M. Lanzillotta, Z.S. Wallace, M. Ebbo, G.J. Webster, F.M. Valle, M.K. Nayar, C.A. Perugino, V. Rebours, X. Dong, Y. Wu, Q. Li, N. Rampal, D. Cimbora, and E.L. Culver

N Engl J Med 2025;392:1168-1177

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
03/26/2025
Course expires: 
03/27/2027

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please sign in or create an account to take the course.